Harbin Gloria Pharmaceuticals (002437) Fundamentals 2026 — P/E 15.1x, Revenue Analysis | SniperIQ
Harbin Gloria Pharmaceuticals (002437) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.3B, trading at ¥2.83 on the SHZ. This SniperIQ fundamentals page covers Harbin Gloria Pharmaceuticals's valuation (P/E 15.1x, P/B 2.6x), profitability (net margin 19.4%), revenue (¥2.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Harbin Gloria Pharmaceuticals's market cap?
Harbin Gloria Pharmaceuticals (002437) has a market capitalization of approximately ¥6.3B, trading at ¥2.83 on the SHZ. Market cap moves with the live share price.
What is Harbin Gloria Pharmaceuticals's P/E ratio?
Harbin Gloria Pharmaceuticals's trailing twelve-month P/E ratio is 15.1x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Harbin Gloria Pharmaceuticals?
Harbin Gloria Pharmaceuticals runs a net profit margin of 19.4%, a gross margin of 44.5%, and an operating margin of 20.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Harbin Gloria Pharmaceuticals generate?
Harbin Gloria Pharmaceuticals reported revenue of ¥2.1B for fiscal year 2025, with net income of ¥377M and earnings per share (EPS) of 0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Harbin Gloria Pharmaceuticals pay a dividend?
Harbin Gloria Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Harbin Gloria Pharmaceuticals financially healthy?
Harbin Gloria Pharmaceuticals carries a debt-to-equity ratio of 0.01x and a current ratio of 1.90x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Harbin Gloria Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Harbin Gloria Pharmaceuticals (002437) the key facts are: market cap ¥6.3B, P/E 15.1x, revenue ¥2.1B, 52-week range 2.37-4.08. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Harbin Gloria Pharmaceuticals's full fundamentals live
Get Harbin Gloria Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.